#USA #Ventricular Tachycardia #Cardiff-by-the-Sea #Field Medical #FieldForce

Field Medical Secures $35 Million in Series B Funding

Field Medical, Inc., a clinical-stage innovator in cardiac ablation technologies, has successfully closed a Series B funding round, amassing $35 million. This significant investment, co-led by BioStar Capital and Cue Growth, aims to accelerate the clinical development of their FieldForce™ pulsed field ablation (PFA) platform and propel the company towards its key clinical trials.

Background on Field Medical

Founded in 2022, Field Medical has carved a niche in the medical technology landscape by focusing on advanced cardiac treatments through innovative ablation technologies. The company's lead product, the FieldForce™ Ablation System, is designed to address one of the most challenging areas in electrophysiology: ventricular tachycardia (VT). The system utilizes a cutting-edge pulsed field technology, enabling targeted and efficient ablation procedures that hold promise for improved patient outcomes.

Importance of the Series B Funding

The $35 million raised in this latest funding round will not only facilitate the launch of the essential VERITAS clinical trial but will also enhance the company’s clinical and regulatory capabilities. To date, Field Medical has successfully raised a total of $75 million, showcasing robust investor confidence and support. The Series B funding postures the company to address substantial unmet clinical needs in treating ventricular tachycardia, a condition that remains poorly serviced by existing technologies.

Dr. Steven Mickelsen, the founder and CEO of Field Medical, emphasized the significance of this funding, stating, "Ventricular tachycardia is one of the least penetrated segments in electrophysiology, and there is still a profound lack of tools available to help physicians manage it effectively. Our innovative therapy is designed to meet that need with speed and precision."

Strategic Vision and Future Plans

The recent funding influx aligns perfectly with Field Medical's ambitious vision. The company's strategic focus is aimed at not only advancing their technological capabilities but also redefining patient treatment plans for those suffering from high-risk conditions like VT. This investment supports their readiness for pivotal clinical trials and reflects a solid foundation for commercial growth.

Key Leadership Changes

Accompanying their growth trajectory, Field Medical announced recent changes to its board of directors. The new members bring a wealth of experience in medical technologies and strategic governance. Among them is Mark Wisniewski, Chief Financial Officer of Enterra Medical, who is set to guide the company during this crucial phase of value creation.

Concluding Thoughts

As Field Medical continues to innovate within the cardiac care sphere, their recent funding marks a monumental step forward in the development of advanced therapies for ventricular tachycardia. The support from renowned investors, combined with strategic leadership transformations, sets a robust platform for future developments, ensuring that Field Medical is well-equipped to meet the pressing needs in cardiac care.